Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Idiopathic Pulmonary Fibrosis: early-phase trial registry
22 of 52 indexed Idiopathic Pulmonary Fibrosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #271 of 28,707 conditions by registered trial count.
52 US clinical trials · 22 currently recruiting · #271 of 28,707 conditions by registered trial count
Idiopathic Pulmonary Fibrosis: 52 US clinical trials tracked, 22 recruiting.
Idiopathic Pulmonary Fibrosis is the subject of 52 registered US clinical trials on ClinicalTrials.gov, 22 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 33 in Phase 1-2 (earlier-stage). The most active sponsor is Boehringer Ingelheim, running 5 of these trials.
Enrollment posture brief
Registry condition idiopathic-pulmonary-fibrosis
OPEN 22 | RECR 42% | LATE 5 | EARLY 33 | RANK #271 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Metastatic Pancreatic Cancer (42% recruiting · 33 trials)
Idiopathic Pulmonary Fibrosis lists 22 open slots (42% of 52 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Idiopathic Pulmonary Fibrosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Idiopathic Pulmonary Fibrosis is recruiting above its size-band peers.
22 of 52 indexed trials (42.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Idiopathic Pulmonary Fibrosis trials is spread across many organizations.
Boehringer Ingelheim accounts for 5 of 52 trials (9.6%). 37 distinct sponsors appear on at least one study for this condition label.
-
Typical Idiopathic Pulmonary Fibrosis enrolment sits around 61 participants.
Median target enrolment is 61 among the 52 trials that report a genuine target (sentinel values excluded). 31 of those (59.6%) plan for fewer than 100 participants.
-
Idiopathic Pulmonary Fibrosis research is mostly interventional.
41 interventional and 11 observational studies make up this index (78.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
52 total, page 1 of 2
Pulmonary Fibrosis Foundation Community Registry
Pulmonary Fibrosis Foundation
NCT05382572
A Study of the Natural Progression of Interstitial Lung Disease (ILD)
University of Chicago
NCT00470327
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
Boehringer Ingelheim
NCT06238622
Interstitial Lung Disease Research Unit Biobank
University of Kansas Medical Center
NCT05392881
Mechanisms of Familial Pulmonary Fibrosis
Vanderbilt University Medical Center
NCT03437486
Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)
University of Pittsburgh
NCT00373841
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
AbbVie
NCT07230288
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Mediar Therapeutics
NCT06967805
The Role of Quantitative CT and Radiomic Biomarkers for Precision Medicine in Pulmonary Fibrosis
University of Virginia
NCT06323876
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
Calluna Pharma AS
NCT06736990
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Cumberland Pharmaceuticals
NCT05571059
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
Daewoong Pharmaceutical Co.
NCT05389215
A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNS-3545 in Healthy Participants
Genosco
NCT07225296
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
Boehringer Ingelheim
NCT07036523
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
Cedars-Sinai Medical Center
NCT06567717
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
National Institute of Environmental Health Sciences (NIEHS)
NCT06325696
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
Boehringer Ingelheim
NCT06241560
Dose-Escalation Study of Artesunate Patients With IPF
Joseph C. Wu
NCT05988463
NAL ER IPF Respiratory Function and Safety Study
Trevi Therapeutics
NCT07036029
Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
University of Alabama at Birmingham
NCT04362644
Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
Paul Szabolcs
NCT03500731
Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis
University of Virginia
NCT06853145
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Bristol-Myers Squibb
NCT06003426
PaTH Clinical Data Research Network (CDRN) Idiopathic Pulmonary Fibrosis (IPF) Clinician Patient Partnership Cohort
University of Pittsburgh
NCT02407431
Detection of Early Idiopathic Pulmonary Fibrosis
Temple University
NCT03457935
LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
PureTech
NCT05321420
Yoga Effect on Quality of Life Study Among Patients with Idiopathic Pulmonary Fibrosis
University of Washington
NCT02848625
Xenon MRI and Progressive ILD
Duke University
NCT05241275
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
Hal Chapman
NCT05195918
Genentech Xenon MRI Idiopathic Pulmonary Fibrosis
Duke University
NCT04071769
Atezolizumab for Idiopathic Pulmonary Fibrosis
Cedars-Sinai Medical Center
NCT05515627
Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG Effect
Hal Chapman
NCT06265532
A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking
Boehringer Ingelheim
NCT03958071
A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
Boehringer Ingelheim
NCT05321069
Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Genentech
NCT00287716
Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis
Bristol-Myers Squibb
NCT01766817
Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study
Actelion
NCT00903331
Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Hoffmann-La Roche
NCT02598193
Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis
National Heart, Lung, and Blood Institute (NHLBI)
NCT02315586
GKT137831 in IPF Patients with Idiopathic Pulmonary Fibrosis
University of Alabama at Birmingham
NCT03865927
Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis
Brigham and Women's Hospital
NCT01214187
A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects
The National Institutes of Pharmaceutical R&D Co. Ltd, China
NCT04720443
SD, IL-13 Production Rate in IPF
Novartis Pharmaceuticals
NCT00532233
Zileuton for the Treatment of Idiopathic Pulmonary Fibrosis
University of Michigan
NCT00262405
Palliative Care Planner (PCplanner)
Duke University
NCT05095363
Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.
Hal Chapman
NCT03928847
IPF mHealth Exercise Study
University of Washington
NCT04838275
Randomized, Crossover, Multi-Dose Pharmacokinetics of EXCL-100 Pirfenidone-Sustained Release Tablet and Esbriet in Healthy Volunteers
Excalibur Pharmaceuticals
NCT05428150
A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
Hoffmann-La Roche
NCT02648048
Microaspiration in Pulmonary Fibrosis
University of California, San Francisco
NCT01150591
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 20 |
| Phase 3 | 4 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Idiopathic Pulmonary Fibrosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Idiopathic Pulmonary Fibrosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Idiopathic Pulmonary Fibrosis page
52 registered trials, 22 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 22 Idiopathic Pulmonary Fibrosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Boehringer Ingelheim sponsors the most Idiopathic Pulmonary Fibrosis trials on record, review their full trial history before evaluating a specific study. See Boehringer Ingelheim's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Idiopathic Pulmonary Fibrosis condition card totals 52 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.